TY - JOUR
T1 - iCARDIO Alliance Global Implementation Guidelines on Heart Failure 2025
AU - Chopra, Vijay
AU - Khan, Muhammad Shahzeb
AU - Abdelhamid, Magdy
AU - Abraham, William T.
AU - Amir, Offer
AU - Anker, Stefan D.
AU - Atherton, John J.
AU - Bacal, Fernando
AU - von Bardeleben, Ralph Stephen
AU - Brito, Dulce
AU - Burgos, Lucrecia Maria
AU - Butler, Javed
AU - Costanzo, Maria Rosa
AU - Damasceno, Albertino
AU - Ezekowitz, Justin A.
AU - Hameed, Ishaque
AU - Harikrishnan, Sivadasanpillai
AU - Jaarsma, Tiny
AU - Lala, Anuradha
AU - Piña, Ileana L.
AU - Saldarriaga, Clara
AU - Sim, David
AU - Teerlink, John R.
AU - Tsabedze, Nqoba
AU - Tsutsui, Hiroyuki
AU - Yu, Jing
AU - Zhang, Yuhui
AU - Zubaid, Mohammad
AU - Balankhe, Nikhil
AU - Gomez-Mesa, Juan Esteban
AU - Januzzi, James L.
AU - Konstam, Marvin
AU - Monroe, Rhonda
AU - Ogola, Elijah
AU - Palaniappan, Vinayagam
AU - Petrie, Mark C.
AU - Pinto, Fausto J.
AU - Rajadhyaksha, Girish C.
AU - Rakisheva, Amina
AU - Ramos, Carlos E.
AU - Rossel, Victor
AU - Sato, Naoki
AU - Schulze, P. Christian
AU - Sindone, Andrew
AU - Skouri, Hadi N.
AU - Van Spall, Harriette G.C.
AU - Štaraitė, Aistė
AU - Stevenson, Lynne Warner
AU - Sulaiman, Kadhim
AU - Wang, Tzung Dau
AU - Böhm, Michael
AU - Coats, Andrew J.S.
AU - Zieroth, Shelley
N1 - Publisher Copyright:
© 2025 The Authors
PY - 2025/7
Y1 - 2025/7
N2 - Inconsistencies in healthcare access, varying infrastructure, resource constraints and diverse local practices as well as practical and political issues restrict the global applicability of currently available guidelines. There is a need for universal recommendations that address the unique challenges faced by patients and healthcare providers worldwide. Our iCARDIO Alliance Global Implementation Guidelines emphasize the incorporation of novel therapies, while integrating standard of care with the most up-to-date evidence to enable clinicians to optimize patient care. This document is about heart failure (HF), including acute and chronic heart failure, heart failure with reduced ejection fraction and heart failure with preserved ejection fraction as well as cardiomyopathies. Context-specific recommendations tailored to individual patient needs are highlighted providing a thorough evaluation of the risks, benefits, and overall value of each therapy, aiming to establish a standard of care that improves patient outcomes and reduces the burden of hospitalization in this susceptible population. These guidelines provide evidence-based recommendations that represent a group consensus considering the many other published guidelines that have reviewed many of the issues discussed here, but they also make new recommendations where new evidence has recently emerged. Most importantly these guidelines also provide recommendations on a number of issues where resource limitations may put constraints on the care provided to HF patients. Such “economic adjustment” recommendations aim to provide guidance for situations when “Resources are somewhat limited” or when “Resources are severely limited”. Hence, this document presents not only a comprehensive but also concise update to HF management guidelines thereby aiming to provide a unified strategy for the pharmacological, non-pharmacological, invasive and interventional management of this significant global health challenge that is applicable to the needs of healthcare around the globe.
AB - Inconsistencies in healthcare access, varying infrastructure, resource constraints and diverse local practices as well as practical and political issues restrict the global applicability of currently available guidelines. There is a need for universal recommendations that address the unique challenges faced by patients and healthcare providers worldwide. Our iCARDIO Alliance Global Implementation Guidelines emphasize the incorporation of novel therapies, while integrating standard of care with the most up-to-date evidence to enable clinicians to optimize patient care. This document is about heart failure (HF), including acute and chronic heart failure, heart failure with reduced ejection fraction and heart failure with preserved ejection fraction as well as cardiomyopathies. Context-specific recommendations tailored to individual patient needs are highlighted providing a thorough evaluation of the risks, benefits, and overall value of each therapy, aiming to establish a standard of care that improves patient outcomes and reduces the burden of hospitalization in this susceptible population. These guidelines provide evidence-based recommendations that represent a group consensus considering the many other published guidelines that have reviewed many of the issues discussed here, but they also make new recommendations where new evidence has recently emerged. Most importantly these guidelines also provide recommendations on a number of issues where resource limitations may put constraints on the care provided to HF patients. Such “economic adjustment” recommendations aim to provide guidance for situations when “Resources are somewhat limited” or when “Resources are severely limited”. Hence, this document presents not only a comprehensive but also concise update to HF management guidelines thereby aiming to provide a unified strategy for the pharmacological, non-pharmacological, invasive and interventional management of this significant global health challenge that is applicable to the needs of healthcare around the globe.
KW - Acute heart failure
KW - Chronic heart failure
KW - Guidelines
KW - Heart failure
KW - Therapy
KW - iCARDIO Alliance
UR - https://www.scopus.com/pages/publications/105008568247
U2 - 10.1016/j.hlc.2025.05.094
DO - 10.1016/j.hlc.2025.05.094
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 40533340
AN - SCOPUS:105008568247
SN - 1443-9506
VL - 34
SP - e55-e82
JO - Heart Lung and Circulation
JF - Heart Lung and Circulation
IS - 7
ER -